apollo
logo
0Login
Introducing Our Latest Arrival!
Mabvinra 40 mg Injection 0.4 ml

Mabvinra 40 mg Injection 0.4 ml

Consult Doctor
Prescription drug
 Trailing icon

Composition

ADALIMUMAB-40MG

Consume Type

PARENTERAL

Return Policy

Not Returnable

for this medicine

About Mabvinra 40 mg Injection 0.4 ml

Mabvinra 40 mg Injection 0.4 ml belongs to the class of monoclonal TNF (Tumor necrosis factor) inhibitors that help reduce signs and symptoms of autoimmune disorders. It is primarily used in the treatment of rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, plaque psoriasis, and psoriatic arthritis. This medicine is also used in the treatment of Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, and uveitis.

Mabvinra 40 mg Injection 0.4 ml consists of Adalimumab, which works by inhibiting the TNF-α and TNF-β binding to the cell surface, thereby making the TNF cytokine inactive. This helps reduce inflammation and pain caused by various autoimmune diseases.

Mabvinra 40 mg Injection 0.4 ml may cause certain side effects such as nausea, headache, back pain, upper respiratory tract infections, vision problems, dizziness, pale skin, numbness, chest pain, rash, and injection site reactions. Most of these side effects do not require medical attention or resolve over time. However, if these side effects persist for longer, please consult your doctor on priority. Mabvinra 40 mg Injection 0.4 ml is a parenteral medicine. It will be administered by a trained healthcare doctor. Hence, do not self-administer. Your physician will decide the dose and duration of the medicine based on the type and severity of the condition.

Mabvinra 40 mg Injection 0.4 ml should be avoided if you are allergic to any of its components.  Inform your doctor if you have any history of serious infections, tuberculosis, optimistic infections, cancer, alcoholic hepatitis, hepatitis B virus infection, heart failure, liver, heart, or kidney diseases, or a weak immune system, as it can worsen your health condition. Mabvinra 40 mg Injection 0.4 ml may cause dizziness, so drive only if you are alert and focused. Mabvinra 40 mg Injection 0.4 ml should not be given to children under two years of age as safety has not been established. Consult the doctor if you are pregnant or breastfeeding.

Uses of Mabvinra 40 mg Injection 0.4 ml

Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis, Plaque psoriasis, Crohn’s disease, Uveitis, Ulcerative colitis.

Medicinal Benefits

Mabvinra 40 mg Injection 0.4 ml consists of Adalimumab, which belongs to the class of monoclonal TNF (Tumor necrosis factor) inhibitors. It works by inhibiting the TNF-α and TNF-β binding to the cell surface, thereby making the TNF cytokine inactive. This helps reduce inflammation and pain, redness, and inflammation (swelling) caused by various autoimmune diseases.

Directions for Use

Mabvinra 40 mg Injection 0.4 ml will be administered by a healthcare professional. Do not self-administer.

Storage

Store in a cool and dry place away from sunlight

Side Effects of Mabvinra 40 mg Injection 0.4 ml

  • Tingling or numbness
  • Shortness of breath
  • Vision problems
  • Injection site reactions
  • Headache
  • Nausea
  • Upper respiratory tract infections.
  • Chest pain

Drug Warnings

Mabvinra 40 mg Injection 0.4 ml should be avoided if allergic to it or any other components present. Inform your doctor if you have any history of serious infections, tuberculosis, optimistic infections, cancer, alcoholic hepatitis, hepatitis B virus infection, heart failure, liver, heart or kidney diseases, weak immune system, multiple sclerosis (nerve and muscle disease), or diabetes as it can worsen your health condition. Do not take live vaccines while being treated with Mabvinra 40 mg Injection 0.4 ml to prevent any serious consequences. Mabvinra 40 mg Injection 0.4 ml is not recommended for use in children below two years of age as safety and efficacy are not established. This medicine is not recommended for patients suffering from sepsis as it can worsen the condition.

Drug Interactions

Drug-Drug Interaction: Mabvinra 40 mg Injection 0.4 ml may interact with other immunosuppressants (certolizumab, golimumab, infliximab, rituximab), medicines used to treat rheumatoid arthritis (anakinra), live vaccines, and other TNF inhibitors (abatacept).

Drug-Food Interaction: No interactions found.

Drug-Disease Interaction: Mabvinra 40 mg Injection 0.4 ml should be used with caution in patients with liver or kidney disease, heart failure, multiple sclerosis, diabetes, weak immune system (HIV), hepatitis B, cancer, and serious infections.

Drug-Drug Interactions Checker List

  • CERTOLIZUMAB
  • GOLIMUMAB
  • INFLIXIMAB
  • RITUXIMAB
  • ANAKINRA
  • ABATACEPT

Habit Forming

No

Diet & Lifestyle Advise

  • Exercising regularly helps in muscle stretching that is less likely to spasm, tear and sprain. Mild exercises such as jogging and walking are helpful for muscle stretching.
  • Massages can also be helpful.
  • Avoid freezing and hot temperatures.
  • Avoid wearing tight-fitting clothes; instead, wear loose garments.
  • Rest well and get plenty of sleep.
  • Stay hydrated; drink plenty of water.

Special Advise

  • It is advised to closely monitor the patient for infections like active tuberculosis during and after the treatment, though the patient gets a negative tuberculin test.
  • It is essential to inform your doctor if you have any active viral, bacterial, and fungal infections before starting Mabvinra 40 mg Injection 0.4 ml.

Disease/Condition Glossary

Rheumatoid arthritis: It is an auto-immune disease (the body's immune system attacks its tissue) that causes joint pain and damage. It occurs when the immune system does not work properly. Symptoms of rheumatoid arthritis include pain, swelling, stiffness, deformities and loss of joint function. 

Ankylosing spondylitis: It causes pain and stiffness in the spine. The pain generally starts in the lower back and can spread to the neck, damaged joints, or other body parts. Ankylosing spondylitis symptoms include decreased flexibility, which usually leads to a hunched-forward posture and pain in the back and joints.

Psoriatic arthritis: It is a type of inflammatory arthritis which occurs in patients with psoriasis. It could also occur in patients without psoriasis, particularly in those with a family history of psoriasis. It affects large joints in the lower extremities, the distal joints of toes and fingers, and the back and pelvis. Symptoms include inflammation of joints, difficulty moving, swelling, patches of red, scaly skin and pain.

Plaque psoriasis: Plaque psoriasis is a most common autoimmune condition in which skin cells multiply faster than normal, resulting in white scales and itchy, red, dry patches. Certain medications, infections, skin injury, stress, and tobacco or alcohol use are the common triggers for plaque psoriasis.

Ulcerative colitis: Ulcerative colitis is a serious inflammatory bowel disease causing inflammation in the digestive tract. It produces ulcers on the inner lining of the large intestine, which may cause bleeding and discharge of pus and mucus. The common symptoms include bloody stools, stomach pain, rectal pain, diarrhoea, fever, or weight loss. Additionally, it may cause other problems such as joint pain or swelling, mouth sores, skin problems, decreased appetite, or nausea. Ulcerative Colitis mostly occurs in people between the age of 15 to 30 years.

Crohn’s disease: Crohn’s disease is a type of chronic inflammatory bowel disease that can affect any part of the gastrointestinal tract, from mouth to anus. But mostly occurs in the small intestine and large intestine. The symptoms include blood in stools, stomach cramps, tiredness, diarrhoea, fever, weight loss, or loss of appetite.

Uveitis: The inner wall of the eye's middle layer is called the uvea. Any inflammation in the uvea is known as uveitis. The causes of uveitis could be an eye injury, viral/bacterial infection, or any underlying disease conditions. If untreated, uveitis could lead to loss of vision. Common symptoms include redness, blurry vision, pain, and swelling. Sometimes, it can also occur after eye surgery.

Country of origin

India
Other Info - MAB0028

FAQs

Mabvinra 40 mg Injection 0.4 ml contains Adalimumab, which works by inhibiting the TNF-α and TNF-β binding to the cell surface, thereby making the TNF cytokine inactive.
Mabvinra 40 mg Injection 0.4 ml affects your immune system and makes you more susceptible to infections. Hence, it is not recommended in people with active infections like tuberculosis or abnormal liver enzymes. Mabvinra 40 mg Injection 0.4 ml can also increase the risk of developing cancers; hence, informing your doctor if you have a history of any cancer is essential.

Disclaimer

While we strive to provide complete, accurate, and expert-reviewed content on our 'Platform', we make no warranties or representations and disclaim all responsibility and liability for the completeness, accuracy, or reliability of the aforementioned content. The content on our platform is for informative purposes only, and may not cover all clinical/non-clinical aspects. Reliance on any information and subsequent action or inaction is solely at the user's risk, and we do not assume any responsibility for the same. The content on the Platform should not be considered or used as a substitute for professional and qualified medical advice. Please consult your doctor for any query pertaining to medicines, tests and/or diseases, as we support, and do not replace the doctor-patient relationship.
bannner image

Alcohol

Consult your doctor

It is not known if alcohol interacts with Mabvinra 40 mg Injection 0.4 ml. Please consult the doctor.

bannner image

Pregnancy

Caution

If you are pregnant or planning pregnancy, inform your doctor before receiving Mabvinra 40 mg Injection 0.4 ml. Your doctor may prescribe this medicine if the benefits outweigh the risks.

bannner image

Breast Feeding

Caution

If you are breastfeeding, inform your doctor before receiving Mabvinra 40 mg Injection 0.4 ml.

bannner image

Driving

Not applicable

Mabvinra 40 mg Injection 0.4 ml will be administered in the hospital setting. Hence, driving is not recommended.

bannner image

Liver

Caution

Mabvinra 40 mg Injection 0.4 ml should be used with caution if you have liver disease. Dose adjustment may be needed in patients with liver impairment.

bannner image

Kidney

Caution

Mabvinra 40 mg Injection 0.4 ml should be used with caution if you have kidney disease. Dose adjustment may be needed in patients with liver impairment.

bannner image

Children

Caution

Mabvinra 40 mg Injection 0.4 ml is not recommended in children below two years of age as safety and efficacy are not established. In children above two years of age, it will be administered by the pediatrician. Mabvinra 40 mg Injection 0.4 ml is used in children only for the treatment of juvenile idiopathic arthritis, paediatric Crohn’s disease, and uveitis.

Author Details

Doctor imageWe provide you with authentic, trustworthy and relevant information

Add to Cart